In vitro and in vivo studies of pharmacokinetics and antitumor efficacy of D07001-F4, an oral gemcitabine formulation

Kuang Yang Hsu, Wei Hua Hao, Jong Jing Wang, Shu Ping Hsueh, Pei Jing Hsu, Li Chien Chang, Chang Shan Hsu

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: The chemotherapy agent gemcitabine is currently administered intravenously because the drug has poor oral bioavailability. In order to assess the pharmacokinetics and antitumor activity of D07001-F4, a new self-microemulsifying oral drug delivery system preparation of gemcitabine, this study was performed to compare the effect of D07001-F4 with administered gemcitabine in vitro and in vivo. Methods: D07001-F4 pharmacokinetics was examined by evaluation of in vitro deamination of D07001-F4 and gemcitabine hydrochloride by recombinant human cytidine deaminase (rhCDA) and in vivo evaluation of D07001-F4 pharmacokinetics in mice. Antitumor activity was evaluated by comparing the effect of D07001-F4 and gemcitabine hydrochloride in inhibiting growth in nine cancer cell lines and by examining the effect of D07001-F4 and gemcitabine in two xenograft tumor models in mice. Results: In vitro deamination of D07001-F4 by rhCDA was 3.3-fold slower than deamination of gemcitabine hydrochloride. Growth inhibition by D07001-F4 of 7 of the 8 cancer cell lines was increased compared with that seen with gemcitabine hydrochloride, and D07001-F4 inhibited the growth of pancreatic and colon cancer xenografts. In vivo pharmacokinetics showed the oral bioavailability of D07001-F4 to be 34 %. Conclusions: D07001-F4 was effective against several cancer types, was metabolized more slowly than gemcitabine hydrochloride, and exhibited enhanced oral bioavailability.

Original languageEnglish
Pages (from-to)379-388
Number of pages10
JournalCancer Chemotherapy and Pharmacology
Volume71
Issue number2
DOIs
Publication statusPublished - Feb 2013

Fingerprint

gemcitabine
Pharmacokinetics
Deamination
Cytidine Deaminase
Biological Availability
Heterografts
Neoplasms
Growth
Cells
In Vitro Techniques
Cell Line
Chemotherapy
Drug Delivery Systems
Pancreatic Neoplasms
Colonic Neoplasms

Keywords

  • Cytidine deaminase
  • D07001-F4
  • Gemcitabine
  • SMEDDS

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Cite this

In vitro and in vivo studies of pharmacokinetics and antitumor efficacy of D07001-F4, an oral gemcitabine formulation. / Hsu, Kuang Yang; Hao, Wei Hua; Wang, Jong Jing; Hsueh, Shu Ping; Hsu, Pei Jing; Chang, Li Chien; Hsu, Chang Shan.

In: Cancer Chemotherapy and Pharmacology, Vol. 71, No. 2, 02.2013, p. 379-388.

Research output: Contribution to journalArticle

Hsu, Kuang Yang ; Hao, Wei Hua ; Wang, Jong Jing ; Hsueh, Shu Ping ; Hsu, Pei Jing ; Chang, Li Chien ; Hsu, Chang Shan. / In vitro and in vivo studies of pharmacokinetics and antitumor efficacy of D07001-F4, an oral gemcitabine formulation. In: Cancer Chemotherapy and Pharmacology. 2013 ; Vol. 71, No. 2. pp. 379-388.
@article{498582ff81d748e7bba2f906024fb170,
title = "In vitro and in vivo studies of pharmacokinetics and antitumor efficacy of D07001-F4, an oral gemcitabine formulation",
abstract = "Purpose: The chemotherapy agent gemcitabine is currently administered intravenously because the drug has poor oral bioavailability. In order to assess the pharmacokinetics and antitumor activity of D07001-F4, a new self-microemulsifying oral drug delivery system preparation of gemcitabine, this study was performed to compare the effect of D07001-F4 with administered gemcitabine in vitro and in vivo. Methods: D07001-F4 pharmacokinetics was examined by evaluation of in vitro deamination of D07001-F4 and gemcitabine hydrochloride by recombinant human cytidine deaminase (rhCDA) and in vivo evaluation of D07001-F4 pharmacokinetics in mice. Antitumor activity was evaluated by comparing the effect of D07001-F4 and gemcitabine hydrochloride in inhibiting growth in nine cancer cell lines and by examining the effect of D07001-F4 and gemcitabine in two xenograft tumor models in mice. Results: In vitro deamination of D07001-F4 by rhCDA was 3.3-fold slower than deamination of gemcitabine hydrochloride. Growth inhibition by D07001-F4 of 7 of the 8 cancer cell lines was increased compared with that seen with gemcitabine hydrochloride, and D07001-F4 inhibited the growth of pancreatic and colon cancer xenografts. In vivo pharmacokinetics showed the oral bioavailability of D07001-F4 to be 34 {\%}. Conclusions: D07001-F4 was effective against several cancer types, was metabolized more slowly than gemcitabine hydrochloride, and exhibited enhanced oral bioavailability.",
keywords = "Cytidine deaminase, D07001-F4, Gemcitabine, SMEDDS",
author = "Hsu, {Kuang Yang} and Hao, {Wei Hua} and Wang, {Jong Jing} and Hsueh, {Shu Ping} and Hsu, {Pei Jing} and Chang, {Li Chien} and Hsu, {Chang Shan}",
year = "2013",
month = "2",
doi = "10.1007/s00280-012-2017-5",
language = "English",
volume = "71",
pages = "379--388",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - In vitro and in vivo studies of pharmacokinetics and antitumor efficacy of D07001-F4, an oral gemcitabine formulation

AU - Hsu, Kuang Yang

AU - Hao, Wei Hua

AU - Wang, Jong Jing

AU - Hsueh, Shu Ping

AU - Hsu, Pei Jing

AU - Chang, Li Chien

AU - Hsu, Chang Shan

PY - 2013/2

Y1 - 2013/2

N2 - Purpose: The chemotherapy agent gemcitabine is currently administered intravenously because the drug has poor oral bioavailability. In order to assess the pharmacokinetics and antitumor activity of D07001-F4, a new self-microemulsifying oral drug delivery system preparation of gemcitabine, this study was performed to compare the effect of D07001-F4 with administered gemcitabine in vitro and in vivo. Methods: D07001-F4 pharmacokinetics was examined by evaluation of in vitro deamination of D07001-F4 and gemcitabine hydrochloride by recombinant human cytidine deaminase (rhCDA) and in vivo evaluation of D07001-F4 pharmacokinetics in mice. Antitumor activity was evaluated by comparing the effect of D07001-F4 and gemcitabine hydrochloride in inhibiting growth in nine cancer cell lines and by examining the effect of D07001-F4 and gemcitabine in two xenograft tumor models in mice. Results: In vitro deamination of D07001-F4 by rhCDA was 3.3-fold slower than deamination of gemcitabine hydrochloride. Growth inhibition by D07001-F4 of 7 of the 8 cancer cell lines was increased compared with that seen with gemcitabine hydrochloride, and D07001-F4 inhibited the growth of pancreatic and colon cancer xenografts. In vivo pharmacokinetics showed the oral bioavailability of D07001-F4 to be 34 %. Conclusions: D07001-F4 was effective against several cancer types, was metabolized more slowly than gemcitabine hydrochloride, and exhibited enhanced oral bioavailability.

AB - Purpose: The chemotherapy agent gemcitabine is currently administered intravenously because the drug has poor oral bioavailability. In order to assess the pharmacokinetics and antitumor activity of D07001-F4, a new self-microemulsifying oral drug delivery system preparation of gemcitabine, this study was performed to compare the effect of D07001-F4 with administered gemcitabine in vitro and in vivo. Methods: D07001-F4 pharmacokinetics was examined by evaluation of in vitro deamination of D07001-F4 and gemcitabine hydrochloride by recombinant human cytidine deaminase (rhCDA) and in vivo evaluation of D07001-F4 pharmacokinetics in mice. Antitumor activity was evaluated by comparing the effect of D07001-F4 and gemcitabine hydrochloride in inhibiting growth in nine cancer cell lines and by examining the effect of D07001-F4 and gemcitabine in two xenograft tumor models in mice. Results: In vitro deamination of D07001-F4 by rhCDA was 3.3-fold slower than deamination of gemcitabine hydrochloride. Growth inhibition by D07001-F4 of 7 of the 8 cancer cell lines was increased compared with that seen with gemcitabine hydrochloride, and D07001-F4 inhibited the growth of pancreatic and colon cancer xenografts. In vivo pharmacokinetics showed the oral bioavailability of D07001-F4 to be 34 %. Conclusions: D07001-F4 was effective against several cancer types, was metabolized more slowly than gemcitabine hydrochloride, and exhibited enhanced oral bioavailability.

KW - Cytidine deaminase

KW - D07001-F4

KW - Gemcitabine

KW - SMEDDS

UR - http://www.scopus.com/inward/record.url?scp=84874106254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874106254&partnerID=8YFLogxK

U2 - 10.1007/s00280-012-2017-5

DO - 10.1007/s00280-012-2017-5

M3 - Article

C2 - 23143189

AN - SCOPUS:84874106254

VL - 71

SP - 379

EP - 388

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -